Target intelligence / Profile preview

Influenza B virus hemagglutinin (Victoria lineage) (HA)

Target
HA
Molecular classification
Glycoprotein, Viral envelope protein, Receptor-binding protein, Fusion protein
01

Overview

Influenza B virus hemagglutinin (HA) from the Victoria lineage is a trimeric viral envelope glycoprotein responsible for binding sialic acid receptors on host cells to facilitate attachment and mediating membrane fusion via low-pH-induced conformational changes in its HA1 (receptor-binding and vestigial esterase subdomains) and HA2 (fusion peptide and coiled-coil) subunits. It features conserved structural elements like disulfide bridges, glycosylation sites (e.g., HA1-145 on 150 loop), and ionizable residues for pH sensitivity, with major antigenic sites (120 loop, 150 loop, 160 loop, 190 helix) forming a continuous surface prone to substitutions for immune evasion. Crystal structures (e.g., B/Hong Kong/8/73 at 2.8 Å) reveal differences from influenza A HA, such as fusion peptide positioning and unique disulfides, while Victoria-lineage viruses show key substitutions near the RBS (e.g., 150KN, 203TK) defining antigenic separation from Yamagata lineage.

Other names
B/Victoria hemagglutininInfluenza B Victoria HAB/Hong Kong/8/73 hemagglutinin (related strain example)B/Victoria/2/1987 hemagglutinin
02

Mechanism of action

Neutralizing antibodies bind receptor-binding site (RBS) or antigenic sites to block attachment or fusion

03

Biological functions

Receptor binding (sialic acid-containing receptors for viral attachment)Membrane fusion (low pH-triggered conformational change for viral entry)Antigenicity (evasion via drift in epitopes like 120 loop, 150 loop, 160 loop, 190 helix)
04

Disease associations

Infection (influenza B virus causes seasonal epidemics and respiratory illness)
05

Safety considerations

Antigenic drift via amino acid substitutions (e.g., positions 148, 149, 150, 203) and indels in 160 loop leads to immune escape and vaccine mismatchStructural plasticity in antigenic regions around RBS enables antibody evasion

Beyond the preview

Go deeper on Influenza B virus hemagglutinin (Victoria lineage) (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza B virus hemagglutinin (Victoria lineage) (HA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call